anrenone (7), and 15&agr;‐hydroxycanrenone (8), while Aspergillus alliaceus was able to produce all the seven metabolites. Metabolites 5, 6, and 7 were identified as new compounds. Their structures were elucidated by using different spectroscopic techniques. Substrate 1 and its metabolites 2, 3, and 5–8 were also evaluated for &agr;‐glucosidase inhibitory activity in vitro. Substrate 1 was found to
图形抽象图。没有可用的字幕。亮点
螺内酯 (1) 的
生物转化产生了 3 种新的和 4 种已知的代谢物。评估了底物 1 和代谢物的 &agr;-
葡萄糖苷酶抑制活性。发现化合物 1 是有效的 &agr;-
葡萄糖苷酶
抑制剂 (IC50 = 335 ± 4.3 &mgr;M) .标准药物(
阿卡波糖)与α-
葡萄糖苷酶的IC50 = 840 ± 1.73 μM。摘要 首次利用真菌细胞合成了利尿降压药
螺内酯(1)的衍
生物。筛选了十种不同的真菌
生物转化 1 的能力,其中四种能够产生代谢物 2-8。Gibberella fujikuroi 产生 canrenone (2)、1-dehydrocanrenone (3),Curvularia lunuta 提供化合物 2 和 7&agr;-thio-spironolactone (4),Fusarium lini 产生化合物 2, 3, 1&bgr;-hydroxycanrenone